Acalabrutinib monotherapy in patients with Waldenström macroglobulinemia: a single-arm, multicentre, phase 2 study

Ibrutinib in Previously Treated Waldenström’s Macroglobulinemia

Steven P. Treon, Christina Tripsas, Kirsten Meid et al. · New England Journal of Medicine · 2015 · 931 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +13

Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia

John C. Byrd, Bonnie K. Harrington, Susan O’Brien et al. · New England Journal of Medicine · 2015 · 891 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +13

The genomic landscape of Waldenström macroglobulinemia is characterized by highly recurring MYD88 and WHIM-like CXCR4 mutations, and small somatic deletions associated with B-cell lymphomagenesis

Zachary R. Hunter, Lian Xu, Guang Yang et al. · Blood · 2013 · 480 citations

Life Sciences, Genetics, Molecular Genetics +15

Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial

Michael Wang, Simon Rule, Pier Luigi Zinzani et al. · The Lancet · 2017 · 448 citations · Full text

Medicine, Oncology, Pharmacotherapy +11

Somatic mutations in MYD88 and CXCR4 are determinants of clinical presentation and overall survival in Waldenström macroglobulinemia

Steven P. Treon, Yang Cao, Lian Xu et al. · Blood · 2014 · 381 citations

Life Sciences, Genetics, Molecular Genetics +9